Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sichuan Kelun-Biotech Biopharmaceutical Co FCF Margin % Chart
Sichuan Kelun-Biotech Biopharmaceutical Co Annual Data
Trend
Dec21
Dec22
Dec23
Dec24
Dec25
FCF Margin %
-1,796.57
-38.54
-1.47
-26.43
-14.90
Sichuan Kelun-Biotech Biopharmaceutical Co Semi-Annual Data
HKSE:06990 vs VRTX, REGN, RVMD: FCF Margin % Comparison
For the Biotechnology subindustry, Sichuan Kelun-Biotech Biopharmaceutical Co's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sichuan Kelun-Biotech Biopharmaceutical Co FCF Margin % vs Biotechnology Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sichuan Kelun-Biotech Biopharmaceutical Co (HKSE:06990) has a FCF Margin % of 31.91% as of Jun. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Sichuan Kelun-Biotech Biopharmaceutical Co and its competitors. According to the industry distribution chart, Sichuan Kelun-Biotech Biopharmaceutical Co ranks #99 out of 957 companies in the Biotechnology industry, placing it in the top 10.3%.
Is Sichuan Kelun-Biotech Biopharmaceutical Co's FCF Margin % too high?
Sichuan Kelun-Biotech Biopharmaceutical Co's current FCF Margin % is 31.91%. Based on the distribution chart, Sichuan Kelun-Biotech Biopharmaceutical Co ranks #99 out of 957 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Sichuan Kelun-Biotech Biopharmaceutical Co has a GF Score™ of 44/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sichuan Kelun-Biotech Biopharmaceutical Co's FCF Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Sichuan Kelun-Biotech Biopharmaceutical Co ranks #99 out of 957 companies for FCF Margin %. This places Sichuan Kelun-Biotech Biopharmaceutical Co in the top 10% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Sichuan Kelun-Biotech Biopharmaceutical Co and its competitors. Sichuan Kelun-Biotech Biopharmaceutical Co's current FCF Margin % is 31.91%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sichuan Kelun-Biotech Biopharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Sichuan Kelun-Biotech Biopharmaceutical Co (HKSE:06990) is currently considered Significantly Overvalued. The stock's GF Value™ is HK$254.91, compared to a current price of HK$523.00 — trading 105.2% above its estimated fair value. The current FCF Margin % is 31.91%. Sichuan Kelun-Biotech Biopharmaceutical Co's overall GF Score™ is 44/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Sichuan Kelun-Biotech Biopharmaceutical Co (HKSE:06990), the current FCF Margin % is 31.91% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sichuan Kelun-Biotech Biopharmaceutical Co (HKSE:06990) Overvalued in 2026?
Based on GuruFocus' analysis, Sichuan Kelun-Biotech Biopharmaceutical Co stock appears to be overvalued.
The current stock price of HK$523.00 is trading 105.2% above its estimated GF Value™ of HK$254.91.
GuruFocus considers Sichuan Kelun-Biotech Biopharmaceutical Co to be Significantly Overvalued.
Key valuation signals for HKSE:06990:
FCF Margin %: 31.91%
GF Value™: HK$254.91 vs. price of HK$523.00 (105.2% above fair value)
No single metric tells the full story. See the HKSE:06990 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd is a biopharmaceutical company committed to the R&D, manufacturing, and commercialization of novel drugs to address medical needs in China and globally. It is one of the first movers in the development of antibody-drug conjugates (ADCs), with over a decade of accumulated experience in ADC development. The company takes a systematic, indication-oriented approach to target the world's prevalent or hard-to-treat cancers, and other diseases and conditions affecting a large and underserved population. Currently, the company has two ADC drugs as Core Products, namely, sac-TMT and trastuzumab botidotin.
44GF Score
Get the complete analysis for HKSE:06990
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:06990 has been successfully added to your 
